Minerva Surgical names Kaile Zagger chief commercial officer

Kaile Zagger, new CCO at Minerva Surgical

Women’s health company Minerva Surgical (Nasdaq:UTRS) announced that it appointed Kaile Zagger as its new chief commercial officer.

Zagger’s role includes helping to guide the strategic growth of the company as it advances in the women’s healthcare space.

“We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity while delivering bottom-line results,” said Todd Usen, president and CEO of Minerva Surgical.

Usen, the former Activ Surgical CEO, took over the corner office at Minerva at the beginning of the year. The company develops abnormal uterine bleeding (AUB) treatments. It closed a private placement worth $30 million last month.

“Beyond her professional acumen, Ms. Zagger’s passion for channeling her leadership experience into companies that improve the quality of healthcare for women and children a…

Read more
  • 0

Minerva Surgical closes $30M financing, has new controlling stockholder

Minerva Surgical (Nasdaq:UTRS) announced today that it closed a private placement worth approximately $30 million.

Santa Clara, California-based Minerva sold more than 146.6 million shares of its common stock at $0.0246 per share. Accelmed Partners led the private placement with participation by New Enterprise Associates. The financing makes Accelmed the controlling stockholder of Minerva Surgical.

The financing amounts to $30 million in proceeds before deducting placement agent fees and other expenses payable by the company.

“We are excited to partner with Minerva Surgical and look forward to working with management to improve its operational performance and build a meaningful women’s health platform” said Dr. Uri Geiger, managing partner of Accelmed.

Minerva plans to use the net proceeds to support operations, R&D activities, working capital and other general corporate purposes. It intends to do so with the funds raised together with existin…

Read more
  • 0

Minerva Surgical CEO retires, former Activ Surgical head Todd Usen named as replacement

Minerva Surgical (Nasdaq:UTRS) announced that it appointed Todd Usen to replace retiring President and CEO David Clapper.

Clapper served as president and CEO of the abnormal uterine bleeding (AUB) treatment developer since 2011. Minerva selected Former Activ Surgical CEO Todd Usen to take over those roles and become a member of the board, effective Jan. 2, 2023. Usen announced his departure from Activ earlier this month.

To ensure a smooth transition, Clapper plans to serve in his role through Usen’s first day, according to a news release. He also entered into a consulting agreement for 12 months following his retirement.

“It’s been a great privilege to collaborate with our incredible team to serve Minerva Surgical’s stockholders, customers, and employees, and I am so proud of what we’ve accomplished together,” said Clapper. “I have served over eleven years as CEO, and I feel this is the right time for me to step aside and start a new chapter in my…

Read more
  • 0

SCOTUS preserves assignor estoppel in Minerva Surgical v. Hologic patent case

The front of U.S. Supreme Court in Washington, D.C. (Adobe stock photo)

The U.S. Supreme Court, in its Minerva Surgical v. Hologic ruling today preserved the legal doctrine of assignor estoppel — that inventors who sell patent rights can’t turn around and sue over the validity of the patents.

However, Justice Elena Kagan, in her opinion for the majority, did say that the doctrine has limits.

Get the full story on our sister site Medical Design & Outsourcing. 

Read more
  • 0